Abstract
The innate immune system accounts for the fastest defense response to microbial invasion although, conversely, several pathogens can modulate the host response resulting in a modulation of their survival and propagation. In this regard, some bacterial toxins possess immuno-stimulating properties that have been exploited in terms of vaccine adjuvanticity and induction of specific cytotoxic T lymphocytes. Among these, Bordetella pertussis toxin (PTX) possesses the ability of modulating the immune responses in multiple ways, as demonstrated in vivo as well as in ex-vivo and in vitro experimental systems. In addition, PTX, as well its nontoxic B-oligomer PTX-B and the genetically inactivated PT-9K/129G molecule, have been recently shown to inhibit infection of primary cells, lymphoid organs and cervical tissue by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of the acquired immunodeficiency syndrome. This article focuses on the regulation of the immune response and on the anti-viral properties of PTX and of its nontoxic related molecules as an example of exploitation of a natural bacterial product to combat viral infections.
Keywords: Pertussis toxin, HIV, tat, intracellular signaling, protein kinase C, adjuvant, microbicide.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide
Volume: 10 Issue: 5
Author(s): Massimo Alfano and Guido Poli
Affiliation:
Keywords: Pertussis toxin, HIV, tat, intracellular signaling, protein kinase C, adjuvant, microbicide.
Abstract: The innate immune system accounts for the fastest defense response to microbial invasion although, conversely, several pathogens can modulate the host response resulting in a modulation of their survival and propagation. In this regard, some bacterial toxins possess immuno-stimulating properties that have been exploited in terms of vaccine adjuvanticity and induction of specific cytotoxic T lymphocytes. Among these, Bordetella pertussis toxin (PTX) possesses the ability of modulating the immune responses in multiple ways, as demonstrated in vivo as well as in ex-vivo and in vitro experimental systems. In addition, PTX, as well its nontoxic B-oligomer PTX-B and the genetically inactivated PT-9K/129G molecule, have been recently shown to inhibit infection of primary cells, lymphoid organs and cervical tissue by the human immunodeficiency virus type 1 (HIV-1), the etiological agent of the acquired immunodeficiency syndrome. This article focuses on the regulation of the immune response and on the anti-viral properties of PTX and of its nontoxic related molecules as an example of exploitation of a natural bacterial product to combat viral infections.
Export Options
About this article
Cite this article as:
Alfano Massimo and Poli Guido, Pertussis Toxin (PTX) and its Non-Toxic Derivatives as Vaccine Adjuvant and Microbicide, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (5) . https://dx.doi.org/10.2174/1871523011109050358
DOI https://dx.doi.org/10.2174/1871523011109050358 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Magnetic Field-Assisted Gene Delivery: Achievements and Therapeutic Potential
Current Gene Therapy Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles,Pathophysiology and Therapeutic Choices
Current Neuropharmacology Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Non-IgE Mediated Food Allergy – Update of Recent Progress in Mucosal Immunity
Inflammation & Allergy - Drug Targets (Discontinued) Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier
Current Pharmaceutical Design Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Current Neuropharmacology Immune Modulation by Plasmid DNA-mediated Cytokine Gene Transfer
Current Pharmaceutical Design Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Distinct Functions of Interleukin-10 Derived from Different Cellular Sources
Current Immunology Reviews (Discontinued) Mesenchymal Stem Cells Targeting of Systemic Disorders in Age-related Macular Degeneration
Current Tissue Engineering (Discontinued) PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) Prostanoid Receptors as Possible Targets for Anti-Allergic Drugs: Recent Advances in Prostanoids on Allergy and Immunology
Current Drug Targets Intracellular Redox State as Target for Anti-Influenza Therapy: Are Antioxidants Always Effective?
Current Topics in Medicinal Chemistry Immunotherapy with Peptides in Systemic Lupus Erythematosus
Current Medicinal Chemistry Neuronal Semaphorins Regulate a Primary Immune Response
Current Neurovascular Research Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Current Drug Targets Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor
Current Drug Targets A Current Understanding of Ocular Immune Privilege
Current Immunology Reviews (Discontinued)